María
Moure González
Publications (11) María Moure González publications
2024
-
Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network
Cardiovascular Diabetology, Vol. 23, Núm. 1
2023
-
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study
American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593
2019
-
Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: Results from the prospective garfield-af registry
Journal of the American Heart Association, Vol. 8, Núm. 3
2018
-
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry
Indian Heart Journal, Vol. 70, Núm. 6, pp. 828-835
2017
-
Nutritional status is related to heart failure severity and hospital readmissions in acute heart failure
International Journal of Cardiology, Vol. 230, pp. 108-114
2016
-
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists
British Journal of Haematology, Vol. 174, Núm. 4, pp. 610-623
2012
-
Evidence for a role of advanced glycation end products in atrial fibrillation
International Journal of Cardiology, Vol. 157, Núm. 3, pp. 397-402
2011
-
Manual de diagnóstico y tratamiento de insuficiencia cardíaca crónica
Santiago de Compostela: Complexo Hospitalario Universitario de Santiago de Compostela, 2011
-
Productos de glicación avanzada: nuevo marcador de disfunción renal en pacientes con insuficiencia cardíaca crónica
Medicina Clinica, Vol. 136, Núm. 12, pp. 513-521
-
Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of seattle heart failure score
American Journal of Cardiology, Vol. 107, Núm. 6, pp. 938-944
2010
-
Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels
European Journal of Heart Failure, Vol. 12, Núm. 10, pp. 1092-1100